What HbA1c level diagnoses diabetes?

An HbA1c of 6.5% (48 mmol/mol) or above on two separate occasions — or once in the context of symptomatic hyperglycaemia — meets ADA and WHO diagnostic criteria for type 2 diabetes. HbA1c in the 5.7–6.4% range (39–46 mmol/mol) defines prediabetes. Below 5.7% (39 mmol/mol) is considered normal. These thresholds do not apply during pregnancy, where oral glucose tolerance testing (OGTT) is the standard diagnostic method for gestational diabetes.

Does HbA1c require fasting?

No. HbA1c reflects mean glycaemia over the preceding 2–3 months and is not materially affected by recent food intake, time of day, or fasting status. This is one of its principal practical advantages over fasting plasma glucose — the specimen can be collected at any time of day without dietary preparation, making it logistically simpler for both practitioners and patients.

What conditions cause a falsely low or falsely high HbA1c?

Conditions shortening erythrocyte lifespan — haemolytic anaemia, sickle cell disease, G6PD deficiency, recent blood transfusion, haemorrhage — produce falsely low HbA1c by reducing the time erythrocytes are exposed to ambient glucose. Iron deficiency anaemia and B12 or folate deficiency extend erythrocyte lifespan, producing falsely elevated HbA1c. Haemoglobin structural variants (HbS, HbC, HbE, HbD) interfere with HbA1c measurement in an assay-platform-specific manner. Advanced chronic kidney disease affects HbA1c through haemolysis, EPO therapy effects, and assay interference. When HbA1c appears discordant with fasting glucose or clinical picture, these conditions must be assessed.

What is the HbA1c treatment target for patients with type 2 diabetes?

The ADA recommends an HbA1c target below 7.0% (53 mmol/mol) for most non-pregnant adults with type 2 diabetes. Tighter targets — 6.0–6.5% (42–48 mmol/mol) — are appropriate for younger patients with short disease duration, no cardiovascular disease, and low hypoglycaemia risk who can achieve this without burdensome treatment. Broader targets — 7.5–8.0% (58–64 mmol/mol) — are appropriate for elderly patients, those with hypoglycaemia unawareness, limited life expectancy, or significant comorbidities where intensive glycaemic control poses greater risk than benefit.

Can HbA1c detect prediabetes earlier than fasting glucose?

HbA1c and fasting glucose detect different aspects of glycaemic dysregulation — neither is uniformly superior for prediabetes detection. HbA1c in the 5.7–6.4% range identifies individuals with above-average chronic mean glycaemia; fasting glucose in the 100–125 mg/dL range (impaired fasting glucose) identifies fasting hepatic glucose dysregulation. A significant proportion of individuals are discordant — prediabetic by one criterion but normal by the other. The ADA recommends using either or both tests, and using clinical context to determine which is more informative for a given patient. Fasting insulin adds further sensitivity for insulin resistance identification before either glucose marker becomes abnormal.

How long does it take to receive HbA1c results from LabCorp?

Results are typically available within 1–2 business days from specimen receipt at the LabCorp processing laboratory. HbA1c is a high-throughput automated measurement.

Is HbA1c appropriate for monitoring glycaemic control in patients with sickle cell trait?

This depends on the LabCorp assay platform. Some HPLC methods — including the Bio-Rad Variant II — have been validated for accurate HbA1c measurement in the presence of HbS (sickle cell trait) and other common variants; other immunoassay platforms produce unreliable results. Practitioners should confirm the specific LabCorp assay platform used for this test and its validated accuracy in the presence of relevant haemoglobin variants. When there is uncertainty, fructosamine — which measures glycated albumin over a 2–3 week window — or continuous glucose monitoring are appropriate alternative glycaemic markers in patients with haemoglobin variants.

BML-MET-002metabolic diabetesUSA

Haemoglobin A1c (Glycated Haemoglobin, HbA1c)

Q: What does a haemoglobin A1c test measure?

HbA1c measures the percentage of haemoglobin molecules in red blood cells that have been glycated — bound to glucose — through a slow, non-enzymatic process proportional to ambient blood glucose over the 90–120 day lifespan of the erythrocyte. Because approximately 50% of HbA1c reflects the most recent 30 days and the remainder reflects the preceding 60–90 days, the result provides an integrated 2–3 month index of mean blood glucose rather than a snapshot of current levels, making it substantially more reproducible than single-point fasting glucose.

The Haemoglobin A1c test quantifies the percentage of glycated haemoglobin in whole blood, providing a 2–3 month integrated index of mean blood glucose concentration that is the gold-standard marker for diabetes screening, diagnosis, and long-term glycaemic management. HbA1c below 5.7% is normal; 5.7–6.4% defines prediabetes warranting lifestyle intervention;

Biomarkers

Blood (whole blood)

Sample

1–2 business days

Turnaround

No — HbA1c is not affected by recent food intake or time of day of collection and can be collected at any time without fasting. This is one of the principal practical advantages of HbA1c over fasting plasma glucose for diabetes screening and monitoring.

Fasting

What is the HbA1c test?

The Haemoglobin A1c test quantifies the percentage of glycated haemoglobin in whole blood, providing an integrated 2–3 month index of mean blood glucose concentration that is the established gold standard for diabetes screening, diagnosis, and long-term glycaemic monitoring. Unlike fasting plasma glucose — which reflects a single-time-point glucose level susceptible to acute dietary, stress, and pre-analytical variability — HbA1c reflects the sustained glycaemic environment experienced by erythrocytes over their lifespan, making it substantially more reproducible across collection times of day, fasting states, and acute physiological perturbations. A single HbA1c result provides months of integrated glycaemic information and is not materially affected by recent meal timing, making it the most practical long-term metabolic monitoring marker available through routine clinical laboratory networks. HbA1c serves three distinct clinical roles across the metabolic health continuum. In population screening and primary prevention, HbA1c in the prediabetes range (5.7–6.4%) identifies individuals at high risk of progression to type 2 diabetes and cardiovascular disease — where lifestyle intervention has a documented 58% relative risk reduction for diabetes progression (DPP trial) — at a stage when glycaemia is still fully reversible. In diabetes diagnosis, HbA1c ≥6.5% on two separate occasions meets WHO and ADA diagnostic criteria for type 2 diabetes without requiring fasting glucose confirmation in most clinical contexts. In established diabetes management, HbA1c at 3-monthly or 6-monthly intervals guides pharmacological therapy escalation and de-escalation decisions against individualised treatment targets — typically <7.0% (53 mmol/mol) for most adults with type 2 diabetes, with tighter targets (≤6.5%) for younger patients with short disease duration and wider targets (≤8.0%) for elderly patients, those with hypoglycaemia unawareness, or complex comorbidities.

What does the HbA1c test measure?

HbA1c(Haemoglobin A1c (Glycated Haemoglobin))

Range: Normal: <5.7% (<39 mmol/mol); Prediabetes: 5.7–6.4% (39–46 mmol/mol); Diabetes: ≥6.5% (≥48 mmol/mol) # REVIEWER FLAG: These are ADA diagnostic thresholds, not laboratory reference ranges in the traditional sense — confirm how LabCorp formats HbA1c results on their report. Most platforms report a numerical HbA1c percentage alongside ADA-aligned interpretive categories (normal, prediabetes, diabetes). Confirm whether LabCorp reports IFCC units (mmol/mol) alongside NGSP units (%) as dual reporting, and confirm the specific LabCorp assay methodology — ion-exchange HPLC (e.g. Bio-Rad Variant II) and immunoassay are the dominant platforms; methodology determines susceptibility to haemoglobin variant interference.Optimal: <5.4% (<36 mmol/mol) (functional medicine and preventive cardiology optimal — below the prediabetes threshold and within a range associated with minimal glycation-related end-organ and vascular risk; some integrative practitioners target ≤5.2% for maximum metabolic health). # REVIEWER FLAG: The <5.4% functional optimal is used in integrative and preventive medicine practice but is below any formal clinical guideline intervention threshold — reviewer to confirm appropriate framing. Note that excessively low HbA1c (<4.5%) in the absence of haemolysis raises concern for hypoglycaemia-prone states and should not be interpreted as a target.% / mmol/mol

Haemoglobin A1c is formed by the slow, irreversible, non-enzymatic glycation of the N-terminal valine residue of the beta chain of haemoglobin A — a post-translational modification driven by the Amadori rearrangement of the initial Schiff base adduct formed between glucose and the free amino group. The rate of HbA1c formation is proportional to ambient blood glucose concentration and the lifespan of the erythrocyte — approximately 90–120 days in a healthy adult — producing an integrated index of mean blood glucose over the preceding 2–3 months. HbA1c reflects erythrocyte glucose exposure in a weighted fashion — approximately 50% of HbA1c reflects the most recent 30 days of glycaemia, with the remaining 50% representing the preceding 60–90 days. HPLC-based HbA1c measurement separates glycated haemoglobin fractions by ion-exchange chromatography and is the reference method endorsed by the IFCC for standardisation. Point-of-care HbA1c devices and immunoassay platforms are widely used but subject to greater haemoglobin variant interference.

HbA1c is the cornerstone glycaemic marker for diabetes screening, diagnosis, and treatment monitoring — endorsed by the ADA, EASD, WHO, and every major diabetes guideline as the primary long-term glucose exposure marker. Its 2–3 month integrated reflection of mean glycaemia overcomes the snapshot limitation of fasting glucose, capturing postprandial and nocturnal glucose excursions as well as fasting levels. HbA1c above 6.5% (48 mmol/mol) on two separate occasions — or once alongside a symptomatic hyperglycaemic presentation — meets WHO diagnostic criteria for type 2 diabetes. In established diabetes management, HbA1c guides therapy intensification decisions and is the primary surrogate endpoint in all major diabetes outcome trials — each 1% absolute reduction in HbA1c is associated with approximately 21% reduction in diabetes-related deaths, 14% reduction in myocardial infarction risk, and 37% reduction in microvascular complication risk in the UKPDS cohort. As a cardiovascular risk marker in Boston Heart Diagnostics and functional medicine cardiometabolic panels, HbA1c quantifies the glycaemic contribution to ASCVD risk independent of fasting glucose, with levels in the prediabetes range associated with measurably elevated cardiovascular event rates.

Why is the HbA1c test ordered?

Type 2 diabetes screening in adults with cardiovascular risk factors — overweight or obesity (BMI ≥25 kg/m², or ≥23 kg/m² in Asian populations), physical inactivity, first-degree family history of diabetes, hypertension, dyslipidaemia, PCOS, gestational diabetes history, prediabetes on prior testing, or any established ASCVD
Prediabetes monitoring and progression surveillance — serial HbA1c at 3–6 monthly intervals in patients with confirmed prediabetes undergoing lifestyle modification, metformin therapy, or other prevention intervention, to track glycaemic trajectory and treatment response
Type 2 diabetes diagnosis confirmation — HbA1c ≥6.5% on two separate occasions (or once with symptomatic hyperglycaemia) confirms the diagnosis per ADA and WHO criteria without requiring fasting glucose or oral glucose tolerance test in most clinical scenarios
Established diabetes glycaemic monitoring — 3-monthly HbA1c in patients not at target; 6-monthly in those at stable target — guiding adjustments to pharmacological therapy, dietary intervention, and lifestyle modification
Cardiovascular and cardiometabolic risk stratification — HbA1c as part of a comprehensive cardiometabolic risk panel alongside fasting glucose, fasting insulin, lipids, hs-CRP, and blood pressure in patients with metabolic syndrome, ASCVD risk factors, or family history of premature cardiovascular disease
Pre-surgical and pre-procedural glycaemic assessment — HbA1c before elective surgery, endoscopy, or invasive procedures where poor glycaemic control (HbA1c >8.0–8.5%) predicts elevated post-operative infection risk, impaired wound healing, and adverse cardiovascular outcomes
Gestational diabetes and pre-pregnancy glycaemic assessment — HbA1c as a screening adjunct before conception in high-risk women and in early pregnancy assessment, noting that HbA1c diagnostic thresholds are not endorsed for gestational diabetes diagnosis during pregnancy (OGTT is the standard); HbA1c monitors glycaemic control in pre-existing diabetes in pregnancy
Functional and integrative medicine metabolic baseline — HbA1c alongside fasting insulin, fasting glucose, and HOMA-IR calculation as the foundational glycaemic and insulin resistance assessment, identifying prediabetes and glycaemic trend before fasting glucose abnormality becomes apparent

Sample collection and turnaround

Sample type

Blood (whole blood)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days

Collection notes

Collect into EDTA anticoagulant tube (lavender / purple top). Immediately after collection, gently invert the tube 8–10 times to ensure thorough EDTA mixing and prevent microclot formation — microclots interfere with haematology and HbA1c HPLC separation. Do not shake the tube. Document on the requisition form: (1) known haemoglobin variants — HbS (sickle cell trait or disease), HbC, HbE, HbD, or other haemoglobinopathy — as these require assay platform awareness for result validation; (2) haemolytic anaemia or other conditions shortening erythrocyte lifespan; (3) recent blood transfusion within 3 months — HbA1c is unreliable post-transfusion; (4) iron deficiency status — concurrent ferritin helps interpret elevated HbA1c; (5) current diabetes medications and doses — for treatment response assessment context; (6) CKD stage — advanced CKD affects HbA1c reliability. # REVIEWER FLAG: Confirm LabCorp EDTA tube type (K2-EDTA vs K3-EDTA), minimum whole blood volume, maximum acceptable time from collection to analysis for HbA1c, and whether refrigeration is required for EDTA whole blood specimens before processing.

Specimen requirements

Minimum 1.0 mL EDTA whole blood. Stable at room temperature (18–25°C) for up to 7 days and at 2–8°C for up to 7 days — HbA1c in EDTA whole blood is substantially more stable than fasting glucose specimens, accommodating typical transit times without special cold-chain requirements. Do not freeze EDTA whole blood intended for HbA1c. # REVIEWER FLAG: Confirm minimum volume and stability data with LabCorp assay documentation — stability may vary between HPLC and immunoassay platforms.

What can affect HbA1c results?

reducesHaemolytic anaemia and conditions shortening erythrocyte lifespan

HbA1c reflects cumulative glycation over the erythrocyte lifespan. Any condition that shortens erythrocyte survival — haemolytic anaemia (autoimmune, sickle cell, G6PD deficiency, hereditary spherocytosis), haemorrhage, or post-transfusion — reduces the time erythrocytes are exposed to ambient glucose, producing a falsely low HbA1c that underestimates true mean glycaemia. This is the most clinically consequential HbA1c interference — a patient with haemolytic anaemia and poorly controlled diabetes may appear to have a normal or near-normal HbA1c while experiencing significant hyperglycaemia. Continuous glucose monitoring or fructosamine are alternative glycaemic markers in this setting.

elevatesIron deficiency anaemia and conditions prolonging erythrocyte lifespan

Iron deficiency anaemia reduces erythropoiesis, extending the average erythrocyte lifespan beyond the normal 90–120 days — resulting in prolonged glucose exposure per erythrocyte and a falsely elevated HbA1c that overestimates true mean glycaemia. Similarly, vitamin B12 and folate deficiency — which impair DNA synthesis and delay erythroid maturation — can extend erythrocyte lifespan and modestly elevate HbA1c. This interference is clinically significant: patients with iron deficiency may appear to have prediabetes or poorly controlled diabetes on HbA1c alone. Concurrent ferritin and CBC assessment is essential when HbA1c appears inconsistent with fasting glucose or clinical picture.

variableHaemoglobin variants (HbS, HbC, HbE, HbD)

Structural haemoglobin variants — including HbS (sickle cell trait or disease), HbC, HbE, and HbD — interfere with HbA1c measurement to degrees that are assay-platform-specific. Some HPLC methods accurately measure HbA1c in the presence of variants; immunoassay platforms may produce spuriously low or high HbA1c results when variants are present. Patients of African, Mediterranean, Middle Eastern, or South/Southeast Asian ancestry have higher prevalence of haemoglobin variants — practitioners ordering HbA1c in these populations should be alert to the possibility of haemoglobin variant interference, particularly when HbA1c results are inconsistent with fasting glucose. # REVIEWER FLAG: Confirm LabCorp's specific HbA1c assay platform and its validated accuracy in the presence of common haemoglobin variants — this is clinically critical for accurate reporting in diverse patient populations.

variableChronic kidney disease and uraemia

CKD affects HbA1c through several mechanisms: uraemia induces haemolysis and reduces erythrocyte lifespan (lowering HbA1c); EPO therapy and iron supplementation for renal anaemia alter erythrocyte turnover kinetics; and carbamylation of haemoglobin in uraemia can interfere with some HbA1c assay platforms. The net effect is unpredictable and bidirectional — HbA1c may be falsely low or high in advanced CKD. Fructosamine or continuous glucose monitoring are more reliable glycaemic markers in advanced CKD (eGFR <30 mL/min/1.73m²).

reducesAcute blood loss and recent blood transfusion

Blood transfusion introduces donor erythrocytes that have not been exposed to the recipient's ambient glucose — these cells have zero or minimal glycation, diluting the glycated haemoglobin fraction and producing a falsely low HbA1c. The dilutional effect persists until the transfused erythrocytes are cleared, typically 90–120 days. HbA1c results within 3 months of a blood transfusion are unreliable for glycaemic monitoring. The haemoglobin of the donor erythrocytes may also differ structurally if there is a variant, further complicating the assay.

reducesHigh-dose vitamin C and vitamin E supplementation

Ascorbic acid and alpha-tocopherol inhibit in vivo glycation of haemoglobin through competitive antioxidant mechanisms — high-dose supplementation (above typical dietary intake) can modestly reduce HbA1c independent of glycaemic change. This effect is small in magnitude (typically 0.1–0.3% absolute reduction) and rarely reaches clinical significance, but should be documented in patients on high-dose antioxidant supplementation where small HbA1c changes are being tracked for treatment decisions. # REVIEWER FLAG: Clinical significance of this interaction at typical supplementation doses is debated — reviewer to confirm whether this factor warrants inclusion or should be removed.

What do HbA1c results mean?

Elevated

HbA1c in the prediabetes range (5.7–6.4% / 39–46 mmol/mol) identifies significant cardiometabolic risk and warrants structured lifestyle intervention — the ADA recommends annual HbA1c monitoring, 5–7% body weight reduction if overweight, 150 minutes weekly of moderate-intensity physical activity, and consideration of metformin in patients under 60 years with BMI ≥35 kg/m² or prior gestational diabetes. HbA1c ≥6.5% (≥48 mmol/mol) on two separate occasions confirms type 2 diabetes diagnosis and initiates the treatment pathway — lifestyle modification, metformin initiation, and individualised pharmacological escalation based on comorbidities (cardiovascular disease, CKD, hypoglycaemia risk, weight). HbA1c above 9.0% (75 mmol/mol) in established diabetes indicates significantly suboptimal control with high risk of microvascular and macrovascular complications, and warrants urgent therapy review. HbA1c above 10% (86 mmol/mol) may warrant consideration of initial combination therapy or insulin in symptomatic patients.

Normal

A normal HbA1c (<5.7% / <39 mmol/mol) effectively excludes the diagnosis of diabetes and confirms non-prediabetic glycaemic status. In a patient with metabolic risk factors, a normal HbA1c warrants repeat screening at a minimum of annual intervals given the ongoing risk of progression. In functional medicine, a normal HbA1c in the 5.4–5.7% range with concurrent elevated fasting insulin (HOMA-IR >1.5) identifies compensated insulin resistance — a cardiometabolic risk state not captured by HbA1c alone, where fasting insulin provides the complementary picture. A normal HbA1c does not exclude postprandial glycaemic excursions — patients with reactive hypoglycaemia or postprandial hyperglycaemia may have normal or low HbA1c while experiencing clinically significant glucose dysregulation detectable only by continuous glucose monitoring or 2-hour postprandial glucose.

Reduced

HbA1c below 5.7% (<39 mmol/mol) confirms normal glycaemic status in an individual without a condition shortening erythrocyte lifespan. In the context of active diabetes management, HbA1c below the ADA target of 7.0% (<53 mmol/mol) confirms target achievement. In elderly patients, those with hypoglycaemia unawareness, or those with limited life expectancy, HbA1c below 6.5% (<48 mmol/mol) may be unnecessarily tight — individualised targets are appropriate. An unexpectedly low HbA1c in a patient not on antidiabetic therapy with no reason for shortened erythrocyte lifespan (no anaemia, no transfusion) should prompt a review for haemolytic conditions, haemoglobin variants, or recent blood loss.

Note: The two most clinically impactful interpretive caveats are erythrocyte lifespan alteration and haemoglobin variants. Iron deficiency elevates HbA1c spuriously; haemolysis and transfusion lower it spuriously; haemoglobin variants produce assay-platform-dependent distortions. In any patient where HbA1c appears discordant with fasting glucose, clinical presentation, or known risk factors, the erythrocyte lifespan and haemoglobin variant status must be assessed before clinical decisions are based on the HbA1c alone. The second caveat is the HbA1c:mean glucose relationship — while the equation eAG (mg/dL) = (28.7 × HbA1c%) − 46.7 provides a population-level estimate of mean glucose, individual variation in the HbA1c:mean glucose ratio (so-called 'high' and 'low' HbA1c glycators) means the same HbA1c can correspond to meaningfully different mean glucose levels in different individuals. Continuous glucose monitoring provides the definitive mean glucose and glucose variability data when precision is required.

Frequently asked questions

HbA1c measures the percentage of haemoglobin molecules in red blood cells that have been glycated — bound to glucose — through a slow, non-enzymatic process proportional to ambient blood glucose over the 90–120 day lifespan of the erythrocyte. Because approximately 50% of HbA1c reflects the most recent 30 days and the remainder reflects the preceding 60–90 days, the result provides an integrated 2–3 month index of mean blood glucose rather than a snapshot of current levels, making it substantially more reproducible than single-point fasting glucose.

How to access the HbA1c test

The HbA1c reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: May 24, 2026

Last reviewed: May 24, 2026

References:

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

metabolic diabetes

CMP

The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.

BML-MET-003View reference →

cardiovascular

Lipid Panel

The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…

BML-CAR-003View reference →